1. Home
  2. ABOS vs JYNT Comparison

ABOS vs JYNT Comparison

Compare ABOS & JYNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABOS
  • JYNT
  • Stock Information
  • Founded
  • ABOS 1996
  • JYNT 2010
  • Country
  • ABOS United States
  • JYNT United States
  • Employees
  • ABOS N/A
  • JYNT N/A
  • Industry
  • ABOS Biotechnology: Pharmaceutical Preparations
  • JYNT Multi-Sector Companies
  • Sector
  • ABOS Health Care
  • JYNT Miscellaneous
  • Exchange
  • ABOS Nasdaq
  • JYNT Nasdaq
  • Market Cap
  • ABOS 166.4M
  • JYNT 163.0M
  • IPO Year
  • ABOS 2021
  • JYNT 2014
  • Fundamental
  • Price
  • ABOS $2.52
  • JYNT $11.70
  • Analyst Decision
  • ABOS Strong Buy
  • JYNT Strong Buy
  • Analyst Count
  • ABOS 4
  • JYNT 2
  • Target Price
  • ABOS $9.00
  • JYNT $18.00
  • AVG Volume (30 Days)
  • ABOS 169.4K
  • JYNT 46.8K
  • Earning Date
  • ABOS 08-13-2024
  • JYNT 11-07-2024
  • Dividend Yield
  • ABOS N/A
  • JYNT N/A
  • EPS Growth
  • ABOS N/A
  • JYNT N/A
  • EPS
  • ABOS N/A
  • JYNT N/A
  • Revenue
  • ABOS N/A
  • JYNT $120,071,078.00
  • Revenue This Year
  • ABOS N/A
  • JYNT $0.70
  • Revenue Next Year
  • ABOS N/A
  • JYNT N/A
  • P/E Ratio
  • ABOS N/A
  • JYNT N/A
  • Revenue Growth
  • ABOS N/A
  • JYNT 7.46
  • 52 Week Low
  • ABOS $1.81
  • JYNT $7.31
  • 52 Week High
  • ABOS $5.73
  • JYNT $17.82
  • Technical
  • Relative Strength Index (RSI)
  • ABOS 46.11
  • JYNT 51.57
  • Support Level
  • ABOS $2.15
  • JYNT $10.80
  • Resistance Level
  • ABOS $2.55
  • JYNT $12.02
  • Average True Range (ATR)
  • ABOS 0.16
  • JYNT 0.40
  • MACD
  • ABOS -0.01
  • JYNT 0.14
  • Stochastic Oscillator
  • ABOS 44.12
  • JYNT 81.10

About ABOS Acumen Pharmaceuticals Inc.

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.

About JYNT The Joint Corp.

The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has two operating business segments; the Corporate Clinics segment is comprised of the operating activities of the company-owned or managed clinics, and The Franchise Operations segment is comprised of the operating activities of the franchise business unit. The company generates maximum revenue from the Corporate clinic's segment.

Share on Social Networks: